| Study                         | Design        | N   | Age (years) | FEV1 (Value 1) | FEV1 (Value 2) | Smoking History | Reversibility | Duration (weeks) | Intervention/Comparator                  |
| :---------------------------- | :------------ | :-- | :---------- | :------------- | :------------- | :-------------- | :------------ | :--------------- | :--------------------------------------- |
| Dal Negro et al^24            | R.DB.PG/12    | 18  | 53–77       | 49             |                | No              | No            | 4                | S at 50 μg bid; PL                       |
| Grove et al^25                | R.DB.CO/1     | 29  | 64          | 42             |                | No              | Yes           | 3                | S at 50 μg bid; PL                       |
| Gupta and Chhabra^26          | R.DB.PG/2     | 33  | 58          | 100            | 1.18L          | No              | Yes           | 4                | S at 50 μg bid; PL                       |
| Hanania et al^27              | R.DB.PG.MC/6  | 723 | 64          | 63             | 42             | Yes             | No            | 3                | S at 50 μg bid vs S/F at 50/250 μg bid vs PL |
| Jones and Bosh^28             | R.DB.PG.MC/4  | 283 | 63          | 45             |                | No              | Yes           | 3                | S at 50, 100 μg bid; PL                  |
| Mahler et al^29               | R.DB.PG.MC/3  | 411 | 63          | 74             | 40             | Yes             | Yes           | 4                | S at 42 μg bid; IP at 36 μg qid; PL      |
| Mahler et al^30               | R.DB.PG.MC/6  | 691 | 63          | 66             | 41             | Yes             | No            | 3                | S at 50 μg bid vs S/F at 50/500 μg bid vs PL |
| O’Donnell et al^31            | R.DB.PG.MC/2  | 185 | 64          | 70             | 41             | Yes             | No            | 4                | S at 50 μg bid vs S/F at 50/250 μg bid vs PL |
| Rennard et al^32              | R.DB.PG/3     | 405 | 63          | 63             | 41             | Yes             | Yes           | 5                | S at 42 μg bid; IP at 36 μg qid; PL      |
| Rossi et al^33                | R.DB.PG.MC/12 | 854 | 63          | 83             | 47             | Yes             | Yes (47)      | 3                | F at 4.5 μg bid; PL                      |
| Szafranski et al^34           | R.DB.PG.MC/12 | 812 | 64          | 79             | 36             | Yes             | No            | 3                | F at 4.5/160 μg bid vs PL                |
| Stockley et al^35             | R.DB.PG/3     | 634 | 62          | 76             | 46             | No              | Yes (57)      | 5                | S at 50 μg bid; PL                       |
| Ulrik^36                      | R.DB.CO/2     | 63  | 65          | 45             |                | No              | Yes           | 3                | S at 50 μg bid; PL                       |
| van Noord et al^37            | R.DB.PG.MC/3  | 144 | 64          | 88             | 40             | No              | Yes (38)      | 3                | S at 50 μg bid; PL                       |
| Wadbo et al^39                | R.DB.PG/3     | 183 | 64          | 53             | 33             | No              | Yes (27)      | 3                | F at 18 μg bid; IP at 40 μg qid; PL      |

*R = randomized; DB = double blind; PG = parallel group; CO = cross-over; MC = multicenter; NS = not stated; F = formoterol; S = salmeterol; IP = ipratropium; B = budesonide; PL = placebo; T = tiotropium.

FIGURE 2. Pooled RR for COPD exacerbations requiring withdrawal or hospitalization (with 95% CI) of eligible studies comparing inhaled LABAs with placebo (n = number of exacerbations; N = number of patients). Trials are stratified by type of LABA (salmeterol or formoterol) and reversibility to SABA (poorly reversible or reversible).

이 그림은 흡입 LABA와 위약을 비교한 COPD 악화(중단 또는 입원 필요)의 통합 RR(95% CI)을 보여주는 포레스트 플롯입니다. 연구는 LABA 유형(살메테롤 또는 포모테롤)과 SABA에 대한 가역성(불완전 가역성 또는 가역성)에 따라 층화되었습니다. 각 연구(LABA 유형 및 가역성 하위 그룹별)별로 LABA 군과 위약 군의 악화 수(n/N), 고정 효과 RR(95% CI), Weight% 값을 나타냅니다. 개별 연구의 효과 추정치는 사각형과 신뢰구간 선으로 표시됩니다. 사각형의 크기는 연구의 가중치(Weight%)를 나타냅니다.

**01 Salmeterol vs. Placebo (non-reversible)**
*   **Studies:** Calverley [19], Chapman [22], Stockley [35], van Noord [37]
*   **Subtotal (95% CI):** LABAs 936, Placebo 936
*   **Subtotal RR (fixed) 95% CI:** 0.63 [0.40, 0.99]
*   **Total events:** LABAs 29, Placebo 46
*   **Test for heterogeneity:** Chi^2 = 1.91, df = 3 (P = 0.59), I^2 = 0%
*   **Test for overall effect:** Z = 1.96 (P = 0.05)

| Study or sub-category       | LABAs n/N | Placebo n/N | RR (fixed) 95% CI | Weight % |
| :-------------------------- | :-------- | :---------- | :---------------- | :------- |
| Calverley [19]              | 8/372     | 19/361      | 0.41 [0.18, 0.92] | 6.04     |
| Chapman [22]                | 4/201     | 4/207       | 1.03 [0.26, 4.06] | 1.24     |
| Stockley [35]               | 14/316    | 19/318      | 0.74 [0.38, 1.45] | 5.94     |
| van Noord [37]              | 3/47      | 4/50        | 0.80 [0.19, 3.38] | 1.22     |
| Subtotal (95% CI)           | 936       | 936         | 0.63 [0.40, 0.99] | 14.43    |
| Total events: 29 (LABAs), 46 (Placebo)                               |                 |
| Test for heterogeneity: Chi^2 = 1.91, df = 3 (P = 0.59), I^2 = 0%   |                 |
| Test for overall effect: Z = 1.96 (P = 0.05)                         |                 |

**02 Salmeterol vs. Placebo (reversible)**
*   **Studies:** Brusasco [16], Hanania [27], Mahler [30], O'Donnell [31]
*   **Subtotal (95% CI):** LABAs 799, Placebo 826
*   **Subtotal RR (fixed) 95% CI:** 0.72 [0.54, 0.98]
*   **Total events:** LABAs 64, Placebo 96
*   **Test for heterogeneity:** Chi^2 = 3.36, df = 3 (P = 0.34), I^2 = 10.7%
*   **Test for overall effect:** Z = 2.28 (P = 0.02)

| Study or sub-category       | LABAs n/N | Placebo n/N | RR (fixed) 95% CI | Weight % |
| :-------------------------- | :-------- | :---------- | :---------------- | :------- |
| Brusasco [16]               | 20/405    | 20/400      | 0.99 [0.54, 1.81] | 6.31     |
| Hanania [27]                | 5/177     | 11/185      | 0.48 [0.17, 1.34] | 3.37     |
| Mahler [30]                 | 38/158    | 59/177      | 0.72 [0.51, 1.02] | 17.44    |
| O'Donnell [31]              | 1/59      | 6/64        | 0.18 [0.02, 1.46] | 1.80     |
| Subtotal (95% CI)           | 799       | 826         | 0.72 [0.54, 0.98] | 28.93    |
| Total events: 64 (LABAs), 96 (Placebo)                               |                 |
| Test for heterogeneity: Chi^2 = 3.36, df = 3 (P = 0.34), I^2 = 10.7% |                 |
| Test for overall effect: Z = 2.28 (P = 0.02)                         |                 |

**03 Formoterol vs. Placebo (non-reversible)**
*   **Studies:** Wadbo [39]
*   **Subtotal (95% CI):** LABAs 61, Placebo 60
*   **Subtotal RR (fixed) 95% CI:** 0.72 [0.31, 1.65]
*   **Total events:** LABAs 8, Placebo 11
*   **Test for heterogeneity:** not applicable
*   **Test for overall effect:** Z = 0.78 (P = 0.43)

| Study or sub-category       | LABAs n/N | Placebo n/N | RR (fixed) 95% CI | Weight % |
| :-------------------------- | :-------- | :---------- | :---------------- | :------- |
| Wadbo [39]                  | 8/61      | 11/60       | 0.72 [0.31, 1.65] | 3.48     |
| Subtotal (95% CI)           | 61        | 60          | 0.72 [0.31, 1.65] | 3.48     |
| Total events: 8 (LABAs), 11 (Placebo)                                |                 |
| Test for heterogeneity: not applicable                               |                 |
| Test for overall effect: Z = 0.78 (P = 0.43)                         |                 |

**04 Formoterol vs. Placebo (reversible)**
*   **Studies:** Aalbers [13], Calverley [18], Dahl [23], Rossi [33], Szafranski [34]
*   **Subtotal (95% CI):** LABAs 1781, Placebo 1054
*   **Subtotal RR (fixed) 95% CI:** 0.86 [0.71, 1.04]
*   **Total events:** LABAs 165, Placebo 158
*   **Test for heterogeneity:** Chi^2 = 2.58, df = 4 (P = 0.63), I^2 = 0%
*   **Test for overall effect:** Z = 1.54 (P = 0.12)

| Study or sub-category       | LABAs n/N | Placebo n/N | RR (fixed) 95% CI | Weight % |
| :-------------------------- | :-------- | :---------- | :---------------- | :------- |
| Aalbers [13]                | 1/514     | 0/173       | 1.01 [0.04, 24.77] | 0.23     |
| Calverley [18]              | 73/255    | 79/256      | 0.93 [0.71, 1.21] | 24.71    |
| Dahl [23]                   | 2/386     | 3/200       | 0.35 [0.06, 2.05] | 1.24     |
| Rossi [33]                  | 60/425    | 33/220      | 0.94 [0.64, 1.39] | 13.63    |
| Szafranski [34]             | 29/201    | 43/205      | 0.69 [0.45, 1.06] | 13.35    |
| Subtotal (95% CI)           | 1781      | 1054        | 0.86 [0.71, 1.04] | 53.16    |
| Total events: 165 (LABAs), 158 (Placebo)                             |                 |
| Test for heterogeneity: Chi^2 = 2.58, df = 4 (P = 0.63), I^2 = 0%   |                 |
| Test for overall effect: Z = 1.54 (P = 0.12)                         |                 |

**Overall Total**
*   **Total (95% CI):** LABAs 3577, Placebo 2876
*   **Overall RR (fixed) 95% CI:** 0.78 [0.67, 0.91]
*   **Total events:** LABAs 266, Placebo 311
*   **Test for heterogeneity:** Chi^2 = 9.86, df = 13 (P = 0.71), I^2 = 0%
*   **Test for overall effect:** Z = 3.27 (P = 0.001)

| Total (95% CI) |               |               | 0.78 [0.67, 0.91] | 100.00 |
| :------------- | :------------ | :------------ | :---------------- | :----- |
|                | 3577          | 2876          |                   |        |

근거표 4-3: Indacaterol vs Placebo

| 연구수 | 연구설계   | 비뚤림 위험 | 비일관성 | 비직접성 | 비정밀 | 출판 비뚤림 | 근거수준 |
| :----- | :--------- | :---------- | :------- | :------- | :----- | :---------- | :------- |
| 6      | 무작위대조군 | 없음        | 없음     | 있음     | 있음   | 없음        | 낮음     |

Author, year publication Cope S, 2011

<PAGE>106